Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 20, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, July 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII
June 22, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation’s 2023 Young Investigators Research Forum
June 14, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 14, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced leader sponsorship of...
Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy
June 13, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 13, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the publication of...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy
June 05, 2023 07:00 ET
|
Avadel Pharmaceuticals plc
-LUMRYZ is the first and only once-at-bedtime oxybate for people living with narcolepsy -Once-nightly dosing regimen of LUMRYZ has been found by FDA to provide a major contribution to patient care...
Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 01, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023
May 31, 2023 16:00 ET
|
Avadel Pharmaceuticals plc
– 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growing body of evidence demonstrating positive clinical benefit and patient preference of...
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 04, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
-- Received FDA approval for LUMRYZ™ (sodium oxybate), the first and only once-at-bedtime oxybate for treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy – -- FDA...